Paul Field
Vermögen: 64 $ am 31.08.2026
Vermögen: 64 $ am 31.08.2026
Paul Field was the founder of Bio-Link Partners Ltd., founded in 2005, where the title held was Executive Chairman from 2005 to 2014.
Current jobs include Independent Director at 60 Degrees Pharmaceuticals, Inc. since 2023 and Independent Non-Executive Director at Invion Ltd. starting in 2026.
Former job includes Director at Australian Institute of Co. Directors.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 02.07.2026 | 59 ( 0 % ) | 64 $ | 31.08.2026 |
| Unternehmen | Position | Beginn |
|---|---|---|
| 60 DEGREES PHARMACEUTICALS, INC. | Direktor/Vorstandsmitglied | 12.07.2023 |
| INVION LIMITED | Direktor/Vorstandsmitglied | 19.08.2026 |
| Unternehmen | Position | Ende |
|---|---|---|
Bio-Link Partners Ltd.
Bio-Link Partners Ltd. Miscellaneous Commercial ServicesCommercial Services Operates biotechnology business development company | Gründer | 01.01.2014 |
Australian Institute of Co. Directors
Australian Institute of Co. Directors Miscellaneous Commercial ServicesCommercial Services Promotes governance and develops leadership skills | Direktor/Vorstandsmitglied | - |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
| Private Unternehmen | 4 |
|---|---|
Australian Institute of Co. Directors
Australian Institute of Co. Directors Miscellaneous Commercial ServicesCommercial Services Promotes governance and develops leadership skills | Commercial Services |
Bio-Link Partners Ltd.
Bio-Link Partners Ltd. Miscellaneous Commercial ServicesCommercial Services Operates biotechnology business development company | Commercial Services |
Invion Ltd.
Invion Ltd. Pharmaceuticals: MajorHealth Technology Manufactures drugs for chronic lung diseases | Health Technology |
60 Degrees Pharmaceuticals, Inc.
60 Degrees Pharmaceuticals, Inc. BiotechnologyHealth Technology Develops and commercializes therapeutics for infectious diseases | Health Technology |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen